What Gets Lost: Founder Transitions and Second Chances

The biotech industry talks about founder transitions as maturity milestones. Most of them are not. Most of them are hostile takeovers dressed in governance language, and the people running them often stand to gain from the outcome they are managing.

That is an uncomfortable sentence to write, and I want to earn it before I defend it.

The last two articles in this governance series followed a scientific founder whose work was dismantled. In the article on the scientific voice, he was demoted, excluded, and cut off from the research programme he had created. In the article on "focus", his platform was amputated by operators who could not evaluate what they were looking at. The company went bankrupt. The medicines did not reach patients.

I have not yet told you what happened to him.

Hostile transitions follow the same architecture regardless of company.

The first move is strategic. The new leadership abandons the platform strategy the previous team had built. They call it focus. What they mean is that they do not understand the platform.

The second move is positional. The founder is demoted. CSO becomes scientific advisor. Scientific advisor becomes observer. Observer becomes someone copied on meetings they are not expected to speak at.

The third move is informational. The founder stops receiving the data. Stops being invited to the scientific meetings. Stops being asked the questions that used to come to them by default.

The fourth move, if it happens at all, is financial. Equity that was meant to vest does not vest. Governance mechanisms negotiated in one spirit are invoked against the founder in another.

None of this is accidental. Each step enables the next.

What gets lost is not only institutional knowledge. It is the belief that scientific integrity protects you, when what it actually does is make you inconvenient to people who are not constrained by it.

Years later, the same founder started again. Related science, distinct technology, new company. This time he made a different choice. He did not pick the Chairman with the biggest CV. He picked someone he trusted specifically because he had lived the consequences of not having one.

The criteria for Chairmen, in the hands of a founder who had been destroyed by the wrong one, change completely. Integrity before credentials. Governance fluency before industry profile.

The new company is early-stage. The outcome is uncertain. What matters is what the founder did, and why.

He protected himself structurally first. Board composition chosen with intent, not inherited from a term sheet. Decision rights written down before they became contested. Equity structures designed to preserve alignment rather than extract it. A Chairman chosen for judgment, not convenience.

The lesson governance can teach is one of the hardest. Second chances do not arrive automatically. They arrive because someone who was burned chose to rebuild with better governance, and had the discipline to turn the pain into structural education. The ones who succeed use the first company's governance failures as the second company's governance architecture.

Not all transitions are hostile. The ones that are not require active design. I want to describe what one looks like from the CEO's side.

At Santero, I did not want to lose what Abel Garcia-Pino and Cédric Govaerts had built. Abel in particular spent more than a decade on the structural biology that underpins our entire platform. That depth cannot be hired. It cannot be read off a slide deck. Losing access to it would hollow out the company in ways that would not be obvious for a year or more, by which point the damage would be irreversible.

At the same time, I needed our CSO to own the science going forward. Not nominally. Actually. An executive team cannot function if the people accountable for delivery do not own the decisions. Scientific founders who remain inside the decision flow in an unstructured way, however well-intentioned, run a parallel authority line that erodes the CSO's ability to lead. That is not fair to the CSO, and not fair to the science.

Those two things are in tension. Most CEOs either choose one and lose the other, or they pretend the tension does not exist and manage it through goodwill. Goodwill is not a governance mechanism. When it fails, the founder relationship degrades into the four-step pattern I described earlier.

So I spent time talking to both founders. Properly. A set of deliberate conversations about where the arrangement was working, where it was not, and what was being lost. Cédric was direct with me. He could feel the distance. Both founders were being kept close to the company but not close enough to the data to give the advice they are uniquely placed to give. The interface had a gap, and the gap was costing us the value the founders could still add.

The first structure is a Scientific Problem-solving Forum. Chaired by the CSO. Fortnightly. Three pre-framed questions per session, circulated forty-eight hours in advance. Members: the CSO, the COO, the chemistry lead, and both founders. I do not attend. The purpose is proper scientific debate on the questions that drive the programme. The forum surfaces problems and challenges assumptions. It does not make decisions. Biology decisions remain with the CSO, chemistry decisions with the COO.

The second is a structured advisor feedback process that sits in front of every internal scientific meeting. Slides go to the founders forty-eight hours before the meeting. They respond within twenty-four hours if the issue is urgent, forty-eight hours if it is important but not time-critical. The executive team replies with a clear position: accepted, rejected, or rolled forward to the Forum. Unresolved items have a named destination. Nothing disappears into the assumption that someone will follow up.

What I have deliberately not done is put the founders back inside operational decisions. The CSO owns the science going forward. Abel and Cédric challenge, push back, and call out what the executive team cannot see. That is the classical advisory role, restored to its proper place. The founders accepted that framing, and I do not take that response for granted.

The process of a hostile transition and the process of a graceful one can look similar from the outside. What distinguishes them is intent. Is this transition designed to serve the company, or the people managing it?

A board that cannot answer that question honestly is a board that is probably about to answer it the wrong way.

For scientific founders preparing to step back, protect your voice structurally before you sign anything. Board seat with genuine decision authority. Decision rights over scientific direction. Equity protections that survive role changes. Get it reviewed by a lawyer who has lived through a hostile transition, because they ask better questions than one who has not.

For CEOs inheriting founder-led companies, conduct a proper founder audit first. What does this person know that nobody else does? What relationships depend on them? What parts of the scientific thesis are load-bearing in ways that will not be obvious until you remove them? Every answer is a reason to preserve the founder's role.

Warning signs of hostile dynamics are usually visible early. Founder excluded from strategy discussions that depend on their expertise. "Focus on the science" used as code for "stay in your lane". New leadership spending more energy on founder management than on company management. Any one in isolation might be coincidental. Two together are usually a pattern with a destination.

Every hostile founder transition is a bet that the company is worth more without its creator than with them. In biotech, where the science is the value, that bet almost always loses. The patients who needed the medicines the founder understood rarely get them.

That outcome is not inevitable. It is always a governance choice. Intent without structure cannot survive the next fundraise. Structure without intent hardens into bureaucracy. Graceful transitions need both.

If you are a scientific founder who has navigated a transition, good or bad, your experience matters. What would you tell a founder facing that moment?

This is the fifth article in a six-part series on biotech governance. Next: the red flags I missed, the warning signs I saw and chose not to act on, and what it cost.

I write Beards on Biotech because I have built things that governance destroyed, and because I have been fortunate to work with founders who understood what graceful transitions actually require. If any part of this article has resonated, I would like to hear the story.